- Home
- SUPN vs PZZA Comparison
SUPN vs PZZA Comparison
Compare SUPN & PZZA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- PZZA
- Stock Information
- Founded
- SUPN 2005
- PZZA 1984
- Country
- SUPN United States
- PZZA United States
- Employees
- SUPN N/A
- PZZA N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- PZZA Restaurants
- Sector
- SUPN Health Care
- PZZA Consumer Discretionary
- Exchange
- SUPN Nasdaq
- PZZA Nasdaq
- Market Cap
- SUPN 1.7B
- PZZA 1.5B
- IPO Year
- SUPN 2012
- PZZA 1993
- Fundamental
- Price
- SUPN $32.90
- PZZA $40.80
- Analyst Decision
- SUPN Hold
- PZZA Buy
- Analyst Count
- SUPN 2
- PZZA 13
- Target Price
- SUPN $36.00
- PZZA $56.00
- AVG Volume (30 Days)
- SUPN 787.3K
- PZZA 1.2M
- Earning Date
- SUPN 05-07-2025
- PZZA 05-08-2025
- Dividend Yield
- SUPN N/A
- PZZA 4.54%
- EPS Growth
- SUPN 6500.00
- PZZA 2.42
- EPS
- SUPN 1.32
- PZZA 2.54
- Revenue
- SUPN $661,817,000.00
- PZZA $2,059,387,000.00
- Revenue This Year
- SUPN N/A
- PZZA $3.19
- Revenue Next Year
- SUPN $8.67
- PZZA $3.48
- P/E Ratio
- SUPN $24.90
- PZZA $15.97
- Revenue Growth
- SUPN 8.94
- PZZA N/A
- 52 Week Low
- SUPN $25.53
- PZZA $35.28
- 52 Week High
- SUPN $40.28
- PZZA $68.66
- Technical
- Relative Strength Index (RSI)
- SUPN 46.17
- PZZA 42.87
- Support Level
- SUPN $31.69
- PZZA $44.96
- Resistance Level
- SUPN $32.90
- PZZA $45.32
- Average True Range (ATR)
- SUPN 0.96
- PZZA 1.96
- MACD
- SUPN 0.29
- PZZA -0.50
- Stochastic Oscillator
- SUPN 89.25
- PZZA 2.28
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About PZZA Papa John's International Inc.
Papa John's is one of the largest players in the global QSR, or quick-service restaurant, pizza market, boasting more than 6,000 restaurants across nearly 50 countries at the end of 2024. The firm operates a predominantly franchised system, owning 9% of its restaurants and generating revenue from franchise royalties, sales of pizza and related products at its company-owned stores, and sales from its commissary supply chain. The firm is the fourth-largest limited-service pizza chain globally and third in the US (Euromonitor International), with a sizable presence in the UK, China, South Korea, and Chile.